Decoding Cure Science: A CUREiculum webinar series

The CUREiculum is a suite of tools that provides simple, accessible information on HIV cure research. As part of the effort to increase research literacy around cure, the CUREiculum team, a collaboration of community educators, researchers and advocacy organizations, will be presenting a webinar series that focus on issue-specific topics crucial to understanding the research landscape.

Check out the first three webinars in the series!

Stakeholder Engagement in Cure Research
Friday March 13, 11 am ET
Watch a recording of the webinar!

This webinar, led by Jessica Handibode of AVAC, will discuss how the Good Participatory Practice (GPP) guidelines, developed by UNAIDS and AVAC, can be applied to HIV cure research. GPP provides trial funders, sponsors and implementers with systematic guidance on how to effectively engage with all stakeholders. Drawing from the literature and past HIV prevention trials, the webinar will explore the history and importance of engaging community stakeholders early in the research process.

Latency Reversing Agents
Thursday March 26, 4 pm ET
Watch a recording of the webinar!

This webinar will feature Dr. David Margolis, Principal Investigator of the CARE Collaboratory at University of North Carolina at Chapel Hill, and Dr. Sharon Lewin member of the DARE Collaboratory and Director of the Infectious Disease department at Monash University. Latency reversing agents are biological compounds used to “wake up” HIV infected cells from their resting state in the body. The drugs are used as the “kick”, the first in a two phase strategy often called “kick and kill”. Both researchers will discuss what latency reversing agents are and how the research might contribute to a combination curative strategy.

Early ART
Thursday April 2 at 11 am ET
Watch a recording of the webinar!

Dr. Jintanat Ananworanich, Associate Director for Therapeutics Research at the U.S. Military HIV Research Program (MHRP) of the Walter Reed Army Institute for Research (WRAIR), will present the scientific mechanisms of early treatment and explain how it relates to HIV cure research. Administering early antiretroviral therapy can have a significant impact on limiting the reservoir—the cells that contain non-replicating HIV—in an HIV-positive individual. Starting ART very early after HIV infection has been linked to very low viral loads and even to apparent “remission” (periods of no detectable viral load).

For more information, please contact Jessica ([email protected]) or Karine ([email protected]). The full schedule for the 2015 CUREiculum webinar series is available.

AVAC Report: HIV Prevention on the Line

AVAC’s annual report of the field, the upcoming CROI meeting and why the coming year is the best and worst of times for HIV prevention

Next week, scientists, advocates and clinicians will gather in Seattle for the Conference on Retroviruses and Opportunistic Infections (CROI), a venerable HIV meeting that often triggers media coverage of the AIDS epidemic and the potential for curbing it and preserving health in people living with HIV.

A range of data is expected from CROI including “late-breaker” abstracts that will showcase data from IPERGAY and PROUD, two trials of oral PrEP using TDF/FTC in gay men and other men who have sex with men in Europe and Canada, and another trial of the microbicide 1% vaginal tenofovir gel in South African women. There will also be data from a PrEP “demonstration project” that provided the strategy in a real-life context for Kenyan and Ugandan couples with one HIV-positive and one HIV-negative partner.
We don’t know what the specific headlines will be, but we can say with confidence that one take-away must be this: The future of HIV prevention is on the line.

In our latest report, AVAC Report 2014/15: Prevention on the Line, we provide a clear agenda for what needs to happen, what’s missing, and why it matters now more than ever before.

Specifically, we argue that:

  • Ambitious prevention goals matter. They can galvanize new action, in part by expanding our sense of what’s possible.
  • But these goals will only work if they’re feasible, well-defined, measurable, and backed by adequate resources and political support. The prevention goals issued so far are inspiring but they don’t yet meet those requirements.
  • As the UNAIDS “Fast Track” for 2020 set aspirational goals, clear short-term targets are also urgently needed. We can’t wait for five years to see if the world is on track to end the AIDS epidemic.
  • The global AIDS response is running at a major financial deficit. New targets will not be met—and may even be irrelevant—if we fail to close a growing global funding gap.

Recent breakthroughs in HIV research have transformed the ability to curb new infections, making it possible to contemplate the end of the global AIDS epidemic. But prevention could be left behind if global leadership fails to make it a priority.

Recently, UNAIDS issued broad goals for HIV testing, ART provision and virologic suppression over the next five years. According to the agency, achieving these “90-90-90” goals would put the world on track to effectively end the AIDS epidemic by 2030.

On the prevention front, UNAIDS seeks to reduce new infections worldwide from 2.1 million in 2013 to 500,000 in 2020, and to eliminate stigma and discrimination. These are ambitious goals and worth aspiring to. But something important is missing from the picture—intervention-specific targets with the specificity, strategy and resources to match. The goal is great. What’s missing is how to get there.

In twenty years, we will have ample hindsight as to whether today’s targets mattered in the quest to end AIDS.

But right now, foresight and focus are urgently required. We’re concerned about whether the targets that have been set are the right ones, how much targets matter—particularly in the context of a global response running at a disastrous funding deficit—and where prevention targets other than those focused on the antiretrovirals in HIV-positive individuals—fit in. We’re also cognizant that targets can turn from audacious to absurd in the blink of an eye if financing, political will and community buy-in are missing.

AVAC works in coalitions in many of the countries hardest hit by the epidemic. Targets that are developed Geneva, Washington DC and other corridors of power can bear little resemblance to the realities of AIDS endemic countries and communities. Where there’s no reality, there’s no relevance. It’s essential that countries have the technical and financial resources to make global targets relevant to national context. Otherwise, the loftiest goals will be ignored.

As we argue in this Report, targets have played a critical role in changing the course of the epidemic. Likewise, a poorly-thought out target can have no impact at all. Right now, it’s critical that targets and tactics are matched to the lofty but achievable goal of bringing an end to AIDS. This is why we’ve devoted the first section of the Report to a look at why targets matter, what targets are missing, and how advocates for a comprehensive response need to work together to ensure smart, strategic targets across the spectrum of prevention options.

We also focus on issues that underpin (and, sometimes, undermine) the ability to meet these targets. We identify three specific areas for action:

  • Align high impact strategies with human rights and realities. Biomedical advances of the past eight years have made it scientifically plausible to talk about ending the epidemic. But plausible doesn’t mean possible. Today some scientists and public health professionals are focused on what can be achieved biomedically—without enough attention to the structural and social contexts in which treatment prevention are delivered. At the same time, some rights-focused partners speak of HIV as being exclusively pill-oriented, suggesting that there isn’t any dynamism or action on the rights-based fronts. It need not be a permanent rift—indeed it cannot be. If science does not get synched up with human rights then then there is little hope of bringing the epidemic to a conclusive end.
  • Invest in an oral PrEP-driven paradigm shift. The world is failing to deliver the most effective interventions with smart strategy and at scale. Daily oral PrEP for HIV prevention is just one example. Global targets for PrEP may be released in the coming months, but there aren’t any plans in place to meet them. Demonstration projects are small and disconnected, funding is limited and policy makers aren’t heeding the growing demand from men and women, including young women in Africa. Now is the time to spend and act to fill these gaps.
  • Demand short-term results on the path to long-term goals. It will be years before the world has an AIDS vaccine, cure strategies, long-acting injectable ARVs or multipurpose prevention technologies that reduce the risk of HIV acquisition and provide contraception. But there’s plenty of activity in clinical trials and basic science for these long-term goals. This activity needs to be aligned with short-term goals that can be used to measure progress and manage expectations.

As AVAC Report goes to press this week and as we prepare for CROI next week, the United States is grappling with profound questions about the ways that the lives of Black men and women are valued under the law. The world is trying to understand how the West African Ebola epidemics got out of control—and how to bring them to an end. And there is continued concern and vigilance over anti-homosexuality laws in Nigeria and the Gambia, and in hate-mongering environments and legislation that endanger LGBT individuals and many other marginalized groups around the world.

These events are not separate from the work that we do to fight AIDS. They embody the issues of racism, inequity, poverty and security that drive the epidemic that must be addressed to end it. In addition to the HIV-specific work laid out in these pages, it is essential to work towards fundamental, lasting and positive change in each of these areas. That will be history-making, indeed.

Press Release

With future of HIV prevention “on the line,” AVAC calls for sharper, bolder strategy to end the epidemic

Contacts

Mitchell Warren, [email protected], +1-914-661-1536

Kay Marshall, [email protected], +1-347-249-6375

New York — In a report issued today, AVAC warned that global HIV prevention efforts are in jeopardy due to an absence of strategic targets, resources and specific implementation plans to translate science, slogans and goals into action. The report calls for a robust set of global HIV prevention targets tailored to specific interventions and demands action in several key areas of the global AIDS response, including expanded rollout of daily oral pre-exposure prophylaxis, or PrEP, and alignment of science and human rights-based agendas.

“We’re at a make-or-break moment and the future of HIV prevention is on the line,” said Mitchell Warren, AVAC’s executive director. “Advances in HIV treatment and prevention research have made it possible to contemplate ending the AIDS epidemic in our lifetimes, but that will only happen with smarter planning, increased resources and greater accountability.”

The report was released ahead of the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle (Feb. 23-26), where researchers are expected to present data from several major HIV prevention trials, including studies that could help drive global implementation of PrEP, as well as a key study of a tenofovir-based vaginal gel for women.

Report calls for smart, realistic goals and targets for HIV prevention

Today’s report, entitled Prevention on the Line, takes a close look at global goals for HIV prevention and what it will take to make them a reality. UNAIDS recently adopted the broad goals of reducing new HIV infections worldwide from 2.1 million in 2013 to 500,000 and eliminating stigma and discrimination, both by the year 2020.

Drawing upon lessons from WHO’s “3 x 5” HIV treatment initiative and other case studies, the AVAC Report concludes that ambitious prevention goals are critical – but that they will only work if they’re feasible, well-defined, measurable and supported with adequate resources and political commitment. In the case of the new UNAIDS prevention goals, the report points to a critical need for more specific, interim targets that can be tracked between now and 2020; for better data and monitoring approaches; and for resource allocations that are directly tied to achieving those targets.

“The UNAIDS prevention goals for 2020 are ambitious and inspiring,” said Warren. “But something important is missing from this picture: how to get there. We need a clear path forward, including short-term targets, so we don’t wait five years to see if the world is on track. And new targets won’t be met – and may even be irrelevant – if we fail to close the growing global funding gap for HIV prevention.”

Bold action needed to advance AVAC’s agenda to end AIDS

The report also recommends key actions to advance AVAC’s three-part agenda to end AIDS. First issued in 2011, the agenda calls for sustained efforts to deliver proven prevention tools, demonstrate and roll out new options such as PrEP and develop long-term solutions such as long-acting ARV-based prevention, vaccines and cure strategies.

Key recommendations for 2015 include:

1. Align high-impact HIV prevention with human rights and realities. Research has demonstrated the potential of high-impact prevention strategies, including biomedical approaches like HIV treatment for people living with HIV and voluntary medical male circumcision (VMMC). But these strategies won’t succeed in the real world if we give short shrift to human rights concerns, or if we fail to involve affected communities in designing and implementing prevention programs. Recent experience with treatment and VMMC, in particular, has shown that community buy-in is an essential ingredient of successful rollout and scale-up.

2. Invest now to scale up access to PrEP. Landmark trials have shown that daily oral PrEP is a powerful HIV prevention tool, and studies at next week’s CROI meeting could provide additional support. But the pace of rollout remains far too slow. Demonstration projects are small and disconnected, funding is limited and policy makers are not yet heeding growing demands for access. Funders should invest now in large-scale targeted implementation of PrEP, linked to national programs. National regulatory authorities and health ministries should prioritize licensure and rollout.

3. Accelerate research into long-term solutions. We must sustain and accelerate research on solutions such as an effective AIDS vaccine, long-acting antiretroviral prevention and treatment and a cure. Just like the rest of the AIDS response, this research needs its own short-term targets, aligned to long-term goals.

The new report and related resources, including downloadable graphics, are available now at www.avac.org/report2014-15.

###

About AVAC: Founded in 1995, AVAC is a non-profit organization that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of AIDS vaccines, male circumcision, microbicides, PrEP and other emerging HIV prevention options as part of a comprehensive response to the pandemic.

New Px Wire: Top Ten Things to Watch in 2015

Welcome to the New Year! Wondering where to put your attention and advocacy energy for the next 12 months? We don’t presume to have all the answers, but our new issue of Px Wire includes a highly selective list of ten issues, events and developments to hold attention and spark actions in 2015 — and beyond.

Want to see the bigger picture? Check out our updated timeline of biomedical HIV prevention research in the centerspread!

Download the latest issue of Px Wire here.

Children are Not Tiny Adults – The Science of Finding a Pediatric “Cure” for HIV

The case of the “Mississippi child” has intrigued scientists since Deborah Persaud first announced the child’s lack of detectable virus at the Conference on Retroviruses and Opportunistic Infections in March 2013. The folks behind the CUREriculum, a group of advocacy organizations and the Martin Delany collaboratories, partnering with leading researchers, hosted a pilot webinar on December 3rd to an audience comprised of US based researchers and community members. Kaitlin Rainwater-Lovett, PhD, a translational immunovirologist (she knows how to use basic science to create practical solutions) research fellow in Deborah Persaud’s lab, led an interactive conversation that highlighted the struggles of finding a pediatric “cure” and the strategies the field is pursuing to tackle them. The CUREriculum is scheduled to launch in early 2015.

You can download a copy of the pilot webinar slides here. 

To find out more, contact Jessica Handibode at [email protected] or Karine Dube at [email protected].

HIV Cure Research – An introductory fact sheet

This introductory 2-page document defines cure, reviews the scientific evidence to date, and outlines key research strategies currently being pursued. This fact sheet is part of a series on emerging HIV prevention strategies.

New Px Wire: The state of the prevention union

The new issue of Px Wire, AVAC’s quarterly newsletter on HIV prevention research and implementation, is now available.

Click here to download.

This issue goes to press as global stakeholders in the HIV prevention field are preparing for the HIV Research for Prevention (R4P) conference in Cape Town. HIV R4P is the first-ever meeting to bring together researchers, implementers, policy makers and advocates from across biomedical prevention, including vaccines, microbicides, PrEP, voluntary medical male circumcision, cure and ART in HIV-positive people.

In this issue of Px Wire, we offer a selective “state of the union” update on various areas of the prevention field—highlighting key developments, messages and areas of work that warrant particular joint attention in Cape Town and beyond.

Our centerspread looks at the targets UNAIDS announced at AIDS 2014 in Melbourne—“90- 90-90” targets calling for 90 percent of people with HIV to know their status, get initiated on ART and achieve virologic suppression. Goals such as 90-90-90 help focus the field, and treatment is crucial in ending the epidemic—but this view is incomplete. The field must have the same attention and clear objectives in preventing HIV.

The full issue of Px Wire, as well as our archive of old issues and information on ordering print copies, can be found at www.avac.org/pxwire.

Post AIDS 2014 Webinars: Experts, issues, answers—and more!

The special set of post-AIDS 2014 webinars concluded on Wednesday, October 8. As part of the ongoing Research & Reality series, these webinars gave advocates a chance to talk to leaders from various fields about issues including cure and prevention research, new global targets and more—all of which were raised at the recent International AIDS Conference.

See below for information on and links to slides and recordings from each of the AIDS 2014 webinars. And stay tuned for updates on future installments in the Research & Reality series.

UNAIDS, Targets and Civil Society
In Melbourne, UNAIDS launched a new initiative known as “90-90-90”, which lays out new targets for testing, treatment and virologic suppression. Where did these targets come from, what do they mean—and where does prevention fit in? Chris Collins, Chief of the Community Mobilization Division at UNAIDS addressed these questions and more.
October 8 — Animation: Flash, Audio: MP3, Slides: PDF

Data and Uncertainty: Understanding updates on hormonal contraceptives and HIV
AIDS 2014 featured analyses of data on the potential relationship between hormonal contraceptives and risk of HIV infection. Researchers Charles Morrison (FHI 360) and Kristin Wall (Emory University), and Mary Lyn Gaffield from the WHO discussed the newest findings and guidance.
October 1 — Animation: Flash, Audio: MP3, Slides: PDF

Results of the iPrEx open-label extension (iPrEx OLE): PrEP uptake, sexual practices and HIV incidence
Get details on the iPrEx OLE study from principal investigator Robert Grant, who presented the data at AIDS 2014. The first open-label PrEP study to publish results, these data from iPrEx OLE begin to answer a number of questions on PrEP use in the “real world”.
September 24 — Animation: Flash, Audio: MP3, Slides: PDF

Latest developments in VMMC research and implementation
AIDS 2014 brought more updates on voluntary medical male circumcision (VMMC) including new data on risk behaviors in circumcised men, the impact of cash transfers as part of VMMC programming and more. Kenyan researcher and implementer Kawango Agot reviewed the latest findings.
September 17, 2014; — Slides: PDF

State of the Art HIV Cure: Where are we now and where are we going?
The field of cure research is evolving and expanding, with various proposed trials that require informed engagement from many stakeholders. Get an update, discuss research and hear questions answered by plenary speaker Jintanat Ananworanich.
September 3, 2014 — Animation: Flash, Audio: MP3, Slides: PDF

As always, questions or comments are most welcome! 

Cure Science Decoded: A new curriculum for the curious lay-person

Challenged by cure science? A new curriculum designed for non-scientists, advocates and cure-enthusiasts of all sorts could be just what you are looking for! This new curriculum is a collaborative project that brings together advocacy organizations (AVAC, Project Inform, TAG, NAPWHA, iBase and members of the Martin Delaney Collabratories (MDC) – such as CARE, DARE and defeatHIV, with leading researchers in the field. The effort emerged from the recognition that, while the science of HIV cure research has moved rapidly, literacy materials for lay audiences have not kept pace.

The first module in the curriculum was piloted on August 28th, 2014 with the global community advisory board (CAB) of the AIDS Clinical Trials Group (ACTG). “Everybody wants a cure for HIV and has wanted it for more than 30 years. It is important to translate the science to the community and to make sure there is accurate information about HIV cure research circulating to avoid false hopes,” said Jeff Taylor, co-chair of the Collaboratory of AIDS Researchers for Eradication (CARE) CAB and a steering committee member of the curriculum collaborative. The global CAB—which consists of community advisory boards from many countries—has been asking for materials to support local engagement with communities where ACTG-supported cure research is planned or ongoing. The ACTG is one of six clinical networks maintained by the National Institutes of Health and the only network focused on HIV-positive individuals exclusively. The global CAB of the ACTG works with network administration to discuss the research priorities and needs of the communities they represent. The members were excited and positive about the curriculum’s content.

The next pilot will be held on Saturday October 4, 2014 at 8:30am at the US Conference on AIDS being held in San Diego Oct 2-5. Anyone attending USCA is welcome to attend—details can be found in the program.

When completed, the curriculum will contain 17 modules—listed below. More pilots will be held in the months to come. The curriculum is scheduled for a soft launch in February 2015 at the Conference on Retroviruses and Opportunistic Infections taking place in Seattle, Washington. When completed, the curriculum will include participatory games, pre and post evaluations, recorded webinars, and PowerPoint slide decks.

Curriculum modules:

  • HIV/AIDS and Cure Basics
  • Role of Community in HIV Cure Research
  • Informed Consent and HIV Cure Research
  • Stem Cell Transplantation
  • Gene Therapy
  • Shock and Kill or Latency Reversing Agents
  • Concepts in Basic Sciences and Translational Research – The Main Pathways
  • Therapeutic Vaccines and Immune-Based Therapies
  • Measuring the Latent HIV Reservoir
  • HIV Treatment Interruption
  • Participation in HIV Cure Trials
  • Regulatory Issues in HIV Cure Research
  • Early Antiretroviral Therapy

For more information, please contact:

The Big Picture of Small Molecules for Curing HIV Infection

Welcome to the first installment of a periodic series of P-values posts by guest authors. We’ll be featuring scientists, advocates and implementers from around the world. If you’ve got a point of view you’d like to share or a topic you’re expert in and would like to explain, Let us know.

This post is the first of what will be a series of posts from scientists working on cure research. Dr. David Margolis and Karine Dubé of The Martin Delaney Collaboratory of AIDS Researchers for Eradication explain one strategy being pursued by scientists as a possible way to cure HIV. After reading this, if you want to learn more check out this video on related research.

Highly active antiretroviral therapy (HAART) is a true miracle of modern science and has contributed to saving millions of lives worldwide. HAART can successfully reduce plasma HIV-1 levels in adherent HIV-positive patients to below the detection limit of clinical assays. As wonderful as HAART is, it does not clear HIV from the human body, but can only suppress it. HIV remains dormant or latent in around 1 out of every million white blood cells in suppressed patients in the form of HIV provirus that becomes integrated within the human genome (also called the reservoir).

There are several approaches to eradicating latent HIV infection that have been proposed by the Martin Delaney Collaboratories, including, but not limited to: intensification of HIV treatment in the acute phase of infection, gene therapy and stem cell transplantation research as well as latency reserving agents. Latency reversing agents are small pharmacological molecules that would help uncover where HIV is hiding in the cells of HIV-infected patients whose viral load has been suppressed.

The Collaboratory of AIDS Researchers for Eradication – CARE – endorses the approach of small pharmacological molecules to finding a cure for HIV infection. We believe that this method represents the safest, most scalable, and accessible strategy to eradicating HIV in the future. By using established drug discovery tools, we hope to launch a pipeline of small pharmacological molecules to be used in human studies. These small molecules would induce the expression of the replication-competent latent HIV proviral genomes within resting CD4+ T cells and make them susceptible to the immune clearance and the effect of HAART. In the literature, this is also called the “shock and kill” strategy or “induction and clearance.” This method relies on reactivating the rare remaining reservoirs while patients take their HAART.

Our priority is to discover new molecules that are safe and can act alone or in synergy with other drugs to reactivate HIV virus transcription. We screened over 10,000 new pharmacological molecules and we are examining their mechanisms of action. As these new compounds have various levels of potency and toxicity, it is important to evaluate them carefully using cell models and animal models before advancing them into clinical testing. Experiments are being conducted in vitro (in artificial laboratory cell models), ex vivo (in patient’s cells studied in the laboratory) and in vivo (in animal models or real human patients) using various cell lines and animal models, included humanized mice and non-human primates.

The small pharmacological molecules being proposed would act as inducing agents to disrupt the state of proviral latency. Examples of small molecules that have been studied include inhibitors of histone deacetylase (HDAC) that play a role in maintaining HIV in a transcriptionally silent state. For example, Dr. Archin and colleagues demonstrated in a proof-of-concept study that a single dose of the drug vorinostat, an HDAC inhibitor, can disrupt HIV latency in HIV-positive patients on HAART. HDAC inhibitors have several advantages compared to other latency reversing agents. Because they have also been studied extensively as part of anticancer trials, we know more about their toxicological and pharmacological effects at this time.

Studying small pharmacological molecules also means that we need to carefully examine the regulatory pathways for these drugs. For example, the positive transcription elongation factor b (P-TEFb) plays an important role in regulating HIV transcription. When P-TEFb is active, this means that HIV viral transcription is stimulated. Another protein required for HIV expression is NF-κB, which is an activating regulatory protein needed for the transcription of many genes.

We are also studying molecules that induce signaling using the protein kinase C (PKC) pathway. Some of the PCK agonists under investigation include prostatin (which can induce transcription of latent HIV-1 in J-Lat cells and peripheral blood mononuclear cells (PBMCs) from HIV-positive patients on HAART). Two other PKC agonists under study include bryostatin and ingenol; however less is more about these compounds’ ability to safely induce HIV expression in vivo.

At this time, we cannot predict which compounds or combination of compounds may be effective at inducing expression of proviral DNA. We hope to investigate synergy both mechanistically and mathematically. Ideally, the chosen pharmacological molecules will reactivate latent HIV provirus without inducing a global activation of T cells. We also hope to get around the problem of toxicity by using low concentrations of the most effective inducing agents.

Once the HIV provirus is being expressed, the immune system needs to kill the infected cells. It will thus be important to re-invigorate the immune system of HIV-infected patients to ensure an effective immune response, so latency reversing agents can be used with immune-based therapies. For example, some of the immune cells could be expanded ex vivo and then be re-infused into HIV-infected patients.

Scientists within the Collaboratory are also working on ways to improve measures of the HIV reservoir. As of now, the quantitative viral outgrowth assay is the gold standard in terms of measuring replication-competent proviruses from resting CD4+ T cells. We are also using digital droplet PCR testing to quantify HIV DNA.

We are excited about the prospect of studying new latency reversing agents – as well as combinations of agents – that would be capable of aborting the state of HIV proviral quiescence. This strategy offers a diversity of options for the advancement of new compounds into clinical trials. It is also the safest way forward. We believe that small molecules represent the big picture for curing HIV infection.

CARE Website:
www.delaneycare.org

If you have any questions, please send them to:

  • Dr. David Margolis ([email protected]), Principal Investigator, The Collaboratory of AIDS Researchers for Eradication (CARE)
  • Karine Dubé ([email protected]) Program Manager, The Collaboratory of AIDS Researchers for Eradication (CARE)